OncoSec Medical Incorporated (NASDAQ:ONCS) said on Tuesday that it plans to offer for sale a combination of shares of its common stock and warrants in an underwritten public offering.
Subject to market conditions, there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
AGP/Alliance Global Partners is acting as sole book-running manager for the offering.
The late-stage cancer biotechnology company develops intratumoral gene-delivery immunotherapies, including its lead immunotherapy platform TAVO (tavokinogene telseplasmid), which enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886